Hong Li

A/Prof. Dr. Hong Li is a Doctor of Complementary Medicine who graduated from RMIT University in 2020. Since then, he has served as an Associate Professor and Attending Physician at the Chinese Herbal Formulas Teaching and Research Office, School of Traditional Chinese Medicine, Southern Medical University. He is also an Associate/External PhD Supervisor at the School of Science, RMIT University. 

His research focuses on the clinical effects and mechanisms of natural products for cancers, infectious diseases and metabolic diseases through the network-based investigation which links to drug discovery.

Dr Li utilises supercomputers to perform computational modelling and screening to seek the synergistic effects of compounds in natural products. He also investigates the mechanisms of action of Chinese herbal formulae for cancers, infectious diseases and metabolic diseases via network pharmacological analysis.

Awards:
Deputy Vice-Chancellor’s Higher Degree by Research Prize, RMIT University, 2021

Research funding:
- Supercomputer and structure-based multi-ligand molecular modeling for the synergistic effects of Danggui Beimu Kushen Wan and abiraterone in the treatment of castrate-resistant prostate cancer, funded by National Natural Science Foundation of China, from 2023 to 2025, Grant No. 8220140209, CNY 300,000, Principal Investigator;

- Supercomputing structure-based multi-ligands molecular modeling to investigate the cooperativity of Danggui Beimu Kushen Wan and abiraterone for castrate-resistant prostate cancer, funded by China Postdoctoral Science Foundation, from 2022 to 2023, Grant No.: 2022M711534, CNY 80,000, Principal Investigator;

- Supercomputing SMMM technology to explore the synergistic mechanism of Danggui Beimu Kushen Wan with abiraterone in the treatment of CRPC, funded by Guangdong Basic and Applied Basic Research Foundation, China, from 2021 to 2024, Grant No.: 2021A1515110082, CNY 100,000, Principal Investigator; 

- Supercomputer virtual screening and network pharmacology of Danggui Beimu Kushen Wan on Cytochrome P450 family for prostate cancer, funded by Human Resources and Social Security Department of Guangdong Province, China, from 2021 to 2022, no grant number, CNY 100,000, Principal Investigator.

Professional interests:
Young Editorial Board Member
- Traditional Medicine Research
- Medical Data Mining
-Precision Medicine Research
-Food and Medicine Homology

Reviewer for peer-reviewed journals
Frontiers in Pharmacology (SCI, IF: 5.6),Journal of Ethnopharmacology (SCI, IF: 5.4), Frontiers in Nutrition (SCI, IF: 5), Frontiers in Cell and Developmental Biology (SCI, IF: 5.5), Frontiers in Oncology (SCI, IF: 4.7), BMC Complementary Medicine and Therapies (SCI, IF: 3.9), Journal of Pharmacy and Pharmacology (SCI, IF: 3.765), Frontiers in Genetics (SCI, IF: 3.7), Complementary Therapies in Medicine (SCI, IF: 3.6), Frontiers in Cardiovascular Medicine (SCI, IF: 3.6), Alternative Therapies in Health and Medicine (SCI, IF: 1.5), Traditional Medicine Research (ESCI, IF: 1.3), Evidence-based Complementary and Alternative Medicine, Cancer Advances, Precision Medicine Research, Medical Data Mining, Food and Medicine Homology.